Citadel Advisors’s Prestige Consumer Healthcare PBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-500
Closed -$43K 14402
2025
Q1
$43K Buy
+500
New +$41K ﹤0.01% 12466
2024
Q3
Sell
-700
Closed -$48.2K 14959
2024
Q2
$48.2K Buy
700
+600
+600% +$40.6K ﹤0.01% 11800
2024
Q1
$7.26K Sell
100
-1,200
-92% -$80.2K ﹤0.01% 13624
2023
Q4
$79.6K Hold
1,300
﹤0.01% 11231
2023
Q3
$74.3K Hold
1,300
﹤0.01% 11256
2023
Q2
$77.3K Buy
1,300
+1,200
+1,200% +$71.8K ﹤0.01% 11283
2023
Q1
$6.26K Buy
+100
New +$6.24K ﹤0.01% 13820
2021
Q3
Sell
-16,700
Closed -$870K 14428
2021
Q2
$870K Sell
16,700
-600
-3% -$28.8K ﹤0.01% 8714
2021
Q1
$763K Sell
17,300
-1,000
-5% -$42K ﹤0.01% 8757
2020
Q4
$638K Buy
+18,300
New +$650K ﹤0.01% 7688
2018
Q4
Sell
-20,600
Closed -$781K 9595
2018
Q3
$781K Buy
20,600
+12,200
+145% +$461K ﹤0.01% 5960
2018
Q2
$322K Buy
+8,400
New +$283K ﹤0.01% 7093

Other funds holding PBH

Citadel Advisors's PBH Position: Q2 2026 in Review

Citadel Advisors increased its Prestige Consumer Healthcare (PBH) stake by 208% in Q2 2026, buying an estimated $19.6M and bringing the position to 564,157 shares worth $26.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2234.

Citadel Advisors first reported a position in PBH in Q2 2013 and has held it in 47 quarters since. 320 funds tracked by Wall St. Rank hold PBH as of Q2 2026.

  • Citadel Advisors held 564,157 shares of Prestige Consumer Healthcare worth $26.7M as of Q2 2026.
  • Citadel Advisors bought 380,717 Prestige Consumer Healthcare shares in Q2 2026, an estimated $19.6M.
  • Prestige Consumer Healthcare made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2234 holding.
  • Citadel Advisors first reported a position in Prestige Consumer Healthcare in Q2 2013 and has held it in 47 quarters since.
  • 320 funds tracked by Wall St. Rank held Prestige Consumer Healthcare as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.